Todo DSpace

Listar por tema "rituximab"

Mostrando ítems 21-34 de 34

    • Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma 

      Karakatsanis S.J., Bouzani M., Symeonidis A., Angelopoulou M.K., Papageorgiou S.G., Michail M., Gainaru G., Kourti G., sachanas S., Kalpadakis C., Katodritou E., Leonidopoulou T., Kotsianidis I., Hatzimichael E., Kotsopoulou M., Dimou M., Variamis E., Boutsis D., Kanellias N., Dimopoulou M.N., Michali E., Karianakis G., Tsirkinidis P., Vadikolia C., Poziopoulos C., Pigaditou A., Vrakidou E., Economopoulos T., Kyriazopoulou L., Siakantaris M.P., Kyrtsonis M.-C., Anargyrou K., Papaioannou M., Hatjiharissi E., Vervessou E., Tsirogianni M., Palassopoulou M., Stefanoudaki E., Zikos P., Tsirigotis P., Tsourouflis G., Assimakopoulou T., Verrou E., Papadaki H., Lampropoulou P., Dimopoulos M.-A., Pappa V., Konstantopoulos K., Karmiris T., Roussou P., Panayiotidis P., Pangalis G.A., Vassilakopoulos T.P. (2022)
      Background/Aim: Primary mediastinal large Bcell lymphoma (PMLBCL) is an aggressive B-cell non- Hodgkin lymphoma (NHL), whose prognosis has greatly improved since the incorporation of the anti-CD20 monoclonal antibody ...

    • Regulatory B and T lymphocytes in multiple sclerosis: friends or foes? 

      Vasileiadis G.K., Dardiotis E., Mavropoulos A., Tsouris Z., Tsimourtou V., Bogdanos D.P., Sakkas L.I., Hadjigeorgiou G.M. (2018)
      Current clinical experience with immunomodulatory agents and monoclonal antibodies in principle has established the benefit of depleting lymphocytic populations in relapsing–remitting multiple sclerosis (RRMS). B and T ...

    • A revised international prognostic score system for Waldenström’s macroglobulinemia 

      Kastritis E., Morel P., Duhamel A., Gavriatopoulou M., Kyrtsonis M.C., Durot E., Symeonidis A., Laribi K., Hatjiharissi E., Ysebaert L., Vassou A., Giannakoulas N., Merlini G., Repousis P., Varettoni M., Michalis E., Hivert B., Michail M., Katodritou E., Terpos E., Leblond V., Dimopoulos M.A. (2019)
      A staging system was developed a decade ago for patients with Waldenström’s macroglobulinemia (WM), however, since then WM treatments have changed. A revised staging system could better capture prognosis of WM patients in ...

    • Rituximab Administered for Recurrent Membranous Nephropathy in a Kidney Transplant Recipient Did Not Eliminate Donor-Specific Antibodies 

      Giannopoulou M., Tarassi K., Tsouka G., Christodoulidou C., Stefanidis I., Eleftheriadis T. (2022)
      Chronic active antibody-mediated rejection is the leading cause of kidney transplant failure. Although various immunosuppressive agents have been tested, rituximab included, presently there is no effective treatment. There ...

    • Rituximab Treatment for Persistent Scleritis Associated with Rheumatoid Arthritis 

      Iaccheri, B.; Androudi, S.; Bocci, E. B.; Gerli, R.; Cagini, C.; Fiore, T. (2010)
      Purpose: To report a clinical case of a patient with severe scleritis associated with rheumatoid arthritis (RA) refractive to conventional treatment that was treated effectively with rituximab. Methods and Results: A ...

    • The role of B cells in the pathogenesis of systemic sclerosis 

      Sakkas L.I., Bogdanos D.P. (2016)
      Systemic sclerosis (SSc) is characterized by extensive collagen deposition, microvasculopathy and autoantibodies. All three features can be promoted by activation of T cells and B cells. T cells are of Th2 type producing ...

    • The role of Dickkopf-1 in joint remodeling and fibrosis: A link connecting spondyloarthropathies and scleroderma? 

      Klavdianou K., Liossis S.-N., Sakkas L., Daoussis D. (2017)
      Background Dickkopf-1 (Dkk-1) is a soluble inhibitor of the canonical Wnt pathway, which plays critical roles in embryonic development. Evidence suggests that this molecule regulates several aspects of both bone biology ...

    • The second greek–israeli symposium on autoimmunity and rheumatology: Success through synergy 

      Sakkas L.I., Bogdanos D.P., Boumpas D., Mamouris Z., Gkoutzourelas A., Mavropoulos A., Tsouris Z., Liossis S.-N., Daoussis D., Vasilopoulos D., Tektonidou M., Tzioufas A., Efthymiou G., Dardiotis E., Kitas G., Sharif K., Blank M., Karussis D., Rimar D., Slobodin G., Porat-Katz B.-S., Vadasz Z., Amital H., Toubi E., Shoenfeld Y. (2019)
      [No abstract available]

    • Simultaneous clinical resolution of focal segmental glomerulosclerosis associated with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab 

      Arampatzis, S.; Giannakoulas, N.; Liakopoulos, V.; Eleftheriadis, T.; Kourti, P.; Karasavvidou, F.; Matsouka, P.; Stefanidis, I. (2011)
      Background: Although renal involvement in advanced haematological malignancies is common, glomerulonephritis associated with lymphoproliferative disorders is rare, and the related pathogenetic mechanisms are still poorly ...

    • Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis 

      Sakkas L.I. (2016)
      Systemic sclerosis (SSc) is a multisystem disease characterized by extensive collagen deposition in skin and internal organs, fibrointimal microvasculopathy, and activation of the immune system. T cells and B cells can ...

    • Systemic sclerosis: From pathogenesis towards targeted immunotherapies 

      Sakkas, L. I.; Chikanza, I. C.; Platsoucas, C. D. (2012)
      Systemic sclerosis (SSc), a chronic disease with widespread collagen deposition, has three pathogenetic facets: immune activation, microvasculopathy and fibroblast activation. Immune activation and microvasculopathy occur ...

    • Systemic sclerosis: New evidence re-enforces the role of B cells 

      Sakkas L.I., Bogdanos D.P. (2016)
      Systemic sclerosis (SSc) is characterized by widespread fibrosis, microangiopathy (vasospasms and stenosis), and formation of autoantibodies. T cell activation has been shown to contribute to fibrosis and microvasculopathy ...

    • Targeting very early systemic sclerosis: a case-based review 

      Melissaropoulos K., Kraniotis P., Bogdanos D., Dimitroulas T., Sakkas L., Daoussis D. (2019)
      It is unknown whether treatment in very early/early systemic sclerosis (SSc) can affect long-term outcomes. A case-based review was conducted (i) to assess the effect of rituximab (RTX) in very early SSc and (ii) to explore ...

    • Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort 

      Panopoulos S., Chatzidionysiou K., Tektonidou M.G., Bournia V.K., Drosos A.A., Liossis S.-N.C., Dimitroulas T., Sakkas L., Boumpas D., Voulgari P.V., Daoussis D., Thomas K., Georgiopoulos G., Vosvotekas G., Garyfallos A., Sidiropoulos P., Bertsias G., Vassilopoulos D., Sfikakis P.P. (2020)
      Background: European data indicate that systemic sclerosis (SSc)-related death rates are increasing, thus raising concerns about SSc's optimal management. Herein, we describe current treatment modalities and drug survival ...